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Abstract
Background: Chagas Disease, a WHO- and NIH-designated neglected tropical disease, is endemic in Latin America and an
emerging infection in North America and Europe as a result of population moves. Although a major cause of morbidity and
mortality due to heart failure, as well as inflicting a heavy economic burden in affected regions, Chagas Disease elicits scant
notice from the pharmaceutical industry because of adverse economic incentives. The discovery and development of new
routes to chemotherapy for Chagas Disease is a clear priority.
Methodology/Principal Findings: The similarity between the membrane sterol requirements of pathogenic fungi and those
of the parasitic protozoon Trypanosoma cruzi, the causative agent of Chagas human cardiopathy, has led to repurposing
anti-fungal azole inhibitors of sterol 14a-demethylase (CYP51) for the treatment of Chagas Disease. To diversify the
therapeutic pipeline of anti-Chagasic drug candidates we exploited an approach that included directly probing the T. cruzi
CYP51 active site with a library of synthetic small molecules. Target-based high-throughput screening reduced the library of
,104,000 small molecules to 185 hits with estimated nanomolar KD values, while cross-validation against T. cruzi-infected
skeletal myoblast cells yielded 57 active hits with EC50 ,10 mM. Two pools of hits partially overlapped. The top hit inhibited
T. cruzi with EC50 of 17 nM and was trypanocidal at 40 nM.
Conclusions/Significance: The hits are structurally diverse, demonstrating that CYP51 is a rather permissive enzyme target
for small molecules. Cheminformatic analysis of the hits suggests that CYP51 pharmacology is similar to that of other
cytochromes P450 therapeutic targets, including thromboxane synthase (CYP5), fatty acid v-hydroxylases (CYP4), 17a-
hydroxylase/17,20-lyase (CYP17) and aromatase (CYP19). Surprisingly, strong similarity is suggested to glutaminyl-peptide
cyclotransferase, which is unrelated to CYP51 by sequence or structure. Lead compounds developed by pharmaceutical
companies against these targets could also be explored for efficacy against T. cruzi.
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Introduction
The parasitic protozoon Trypanosoma cruzi, the etiological agent
of Chagas Disease, is naturally transmitted by blood-sucking bugs
of the subfamily Triatominae [1]. The range of clinically approved
drugs for both the acute and chronic stage of the disease is limited
and new medications are urgently needed [2–4]. The integrity of
the parasite’s cell membrane depends on specific endogenously
synthesized 24-methylated sterols [5], membrane building blocks
which cannot be entirely substituted by cholesterol scavenged from
the host in the clinically relevant amastigote stage. The sterol
biosynthesis pathway in T. cruzi is thus essential for the survival of
the replicative intracellular amastigote stage in infected human
hosts [5–7]. The similarity between membrane sterol requirements
of T. cruzi and those of pathogenic fungi has led to the idea of
repurposing anti-fungal azole and triazole drugs for Chagas
Disease therapy. For example, posaconazole and ravuconazole
target sterol 14a-demethylase (CYP51), the key enzyme in sterol
biosynthesis, and therefore have potential as therapeutics [8–12].
Inhibitors of CYP51 deplete endogenous 24-methylated sterols in
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the intracellular amastigote stage, resulting in blebbing of the cell
membrane, deterioration of internal membranes and finally in T.
cruzi cell death [13,14].
Commercial anti-fungal drugs of the ‘‘conazole’’ pedigree are
derived from miconazole that was mainly used for topical
treatment of fungal infections [15]. Posaconazole, the most recent
member of this family to be marketed, is considered not only a
valuable addition to the therapeutic armamentarium against
systemic life-threatening fungal infections [16,17], but also is a
clinical trial candidate for Chagas Disease. The anti-chagasic
potency of posaconazole has been demonstrated in an animal
model of T. cruzi infection [9,18,19] and in humans [12].
However, potential issues of drug resistance, cost and safety mar
the prospective utility of azole drugs. To broaden the range of
CYP51 inhibitors that could be used most efficaciously to treat
patients with Chagas Disease, we employed an approach that
relies on directly probing the CYP51 active site with diverse
compounds to define the chemical and structural space accessible
to inhibitors. This approach is based on advances in high
throughput screening, medicinal chemistry, structural biology,
and cheminformatics, and with it we have identified a broad
selection of promising molecular scaffolds.
As a member of the P450 family, CYP51 shares the common
spectral property of P450 enzymes in which the ferric Fe Soret
band is shifted following the displacement (type I shift) or
replacement (type II shift) of a water molecule, a weak axial
ligand, by a stronger one, usually one containing a nitrogen
aliphatic or aromatic group [20]. The concentration-dependence
of the spectral changes allows the binding affinities of the ligand to
be estimated. A spectroscopic assay utilizing these properties has
been routinely used to explore P450-ligand interactions in low-
throughput format. Three major advantages of the assay that
make it attractive for high-throughput applications are its
simplicity, applicability to poorly characterized enzymes, and
universality, as it can be easily adapted for analysis of any CYP
obtainable in soluble form. The main drawbacks of the assay,
however, are the relatively low-throughput and inherently low
sensitivity of UV-vis absorption spectroscopy, which requires
micromolar protein concentrations for screening. This in turn
leads potentially to interference with test compound optical
properties or solubility and to increased numbers of false-positive
and false-negative hits [21]. Despite these disadvantages, a high
throughput screening (HTS) assay based on the shift of the heme
iron Soret band in response to small molecule binding has been
successfully applied to CYP51’s counterpart in Mycobacterium
tuberculosis [22], ultimately resulting in identification of a potent
T. cruzi inhibitor [14,23] whose drug-like properties for Chagas
Disease are currently being optimized.
The successful development of a structurally characterized, high
expression recombinant T. cruzi CYP51 [24] has led to the
establishment of an experimental platform for direct high-
throughput exploration of the CYP51 active site capable of
accommodating larger and more diverse libraries. Here we
describe how a library of ,104,000 small molecules was reduced
to 185 structurally diverse positive hits with estimated KD values in
the nanomolar range. Cross-validation of hits against T. cruzi
parasites cultured in mammalian cells revealed 57 hits with anti-T.
cruzi activity defined by EC50 values below 10 mM. While a region
of structural similarity among the high affinity hits is dictated by
the requirement for an aromatic heterocycle capable of coordi-
nating to the heme iron, other parts of the molecules are not so
constrained, allowing for unprecedented structural diversity
among potential hits and opening new horizons for medicinal
chemistry exploration of CYP51.
Materials and Methods
CYP51 target expression and purification
A previously constructed expression vector [24] was used to
generate the recombinant T. cruzi CYP51 described in this work.
The CYP51 utilized in the HTS screens had the first 21 residues
upstream of K22 replaced with the fragment MAKKKKK and
was His6-tag-engineered at the C-terminus. Protein was purified as
described elsewhere [24] and was observed by means of 12% SDS-
PAGE to be virtually homogeneous. Chromatographic fractions
containing CYP51 in 20 mM potassium phosphate, pH 8.2, 10%
glycerol, 0.5 mM EDTA, and 1 mM DTT and 200 mM NaCl
were combined, concentrated and stored at 280uC. As expected,
the enzyme solution displayed an absorbance peak at 420 nm,
with a 449 nm peak appearing after reduction with sodium
dithionite and bubbling with CO [24]. The concentration of
functional P450 was determined from difference spectra using the
extinction coefficient e450–490 = 91000 M
21 cm21 [25]. Purified
CYP51 was shown to be stable under screening conditions at room
temperature for up to 4 hours.
High-throughput assay overview
The compound library of the UCSF Small Molecule Discovery
Center (SMDC), consisting of 103,986 diverse small molecules
purchased from ChemBridge (San Diego, California), ChemDiv
(San Diego, California) and SPECS (Delft, Netherlands) was
screened against recombinant T. cruzi CYP51 in 384-well format
using the protocol developed for M. tuberculosis CYP51 and
described elsewhere [21]. The following modifications were
introduced in the protocol to improve signal-to-noise ratio,
throughput and reproducibility of measurements. First, the
working protein concentration was increased to 2 mM and
compounds were screened at 12.5 mM using two-wavelength
detection. In this primary screen, plate reading was performed at
425 nm and 390 nm, corresponding to the maxima and minima
of the difference spectra resulting from type II binding in the
CYP51 active site (Figure 1). Type II inhibitors are characterized
Author Summary
Chagas Disease is the leading cause of heart disease in
Latin America and an emerging infection in Europe and
North America. The clinical presentation of Chagas Disease
arises from infection by the protozoan parasite Trypano-
soma cruzi, which leads to progressive cardiomyopathy. No
vaccine is available and chemotherapeutic options are
limited to the drugs benznidazole and nifurtimox, which
are used during the acute phase but may cause severe
gastrointestinal and neurological side effects and are not
commonly used in the chronic phase. Neither drug is
approved by the FDA for use in the United States. The
need for effective new therapy is urgent. A validated
therapeutic target in T. cruzi is CYP51, an essential enzyme
in the sterol biosynthesis pathway. We report results of
high-throughput screening of small molecules directly
against CYP51, confirmed by in vitro medium-throughput
screening of the hits against T. cruzi-infected mammalian
cells. We have identified a potent T. cruzi inhibitor as well
as a diverse collection of low molecular weight hits with
high affinity to CYP51. We have applied computational
chemistry to relate CYP51 to other pharmacologic targets.
This analysis allowed us to identify molecules already
produced by pharmaceutical companies for future exper-
imental testing against T. cruzi.
Target-Based Small-Molecule Screen against CYP51
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by their coordination bond to the heme iron, the single strongest
interaction contributing to target affinity. Next, to account for
organic solvent effects, protein background and the optical
properties of test compounds, plates were prepared in duplicate,
with target protein loaded in only a single set. After being read and
processed separately, values generated from the protein-minus
reference plate were subtracted from the corresponding values in
the protein-plus test plate, yielding absorbance contributions due
solely to the protein-compound interactions (Figure 1). Finally, to
validate two-wavelength positive hits, four serial dilutions ranging
from 2 mM to 12.5 mM were tested for a subset of positive hits
using spectral detection mode, the spectra being recorded between
350 nm and 500 nm.
Plate design, preparation and reading
All measurements were conducted in 100 mM potassium
phosphate, pH 7.5, supplemented with 10% glycerol and,
according to the plate layout shown in Figure 1, with dimethyl
sulfoxide (DMSO) (columns 1 and 2), reference compound
(columns 23–24) or individual test compounds (columns 3 through
22) at required concentrations. First, buffer alone (reference plates)
or buffer containing 2 mM CYP51 (sample plates) was distributed
in 80 ml aliquots using a Wellmate liquid dispenser (Thermo Fisher
Matrix). Then test compounds, reference or DMSO were added in
1-ml aliquots using the automated 384-well head pipettor (Biomek
FXP, Beckman Coulter) fitted with P20 tips (Fluotics Inc.). The
compound {a-[(4-methylcyclohexyl)carbonyl amino]-N-4-pyridi-
nyl-1H-indole-3-propanamide} purchased from ChemDiv (#
C155-0123) (San Diego, California), referenced previously as
LP-10 [14,23,26], was used as a type II reference. The compound
and the reference stock solutions were prepared in DMSO at
concentrations 80 times above working concentrations. DMSO
alone was used as needed to hold DMSO concentration constant
at 1.25% across the wells. Once prepared, plates were vortexed for
3 min, 800 rpm in a titer plate shaker (Lab-line Instrument, Inc.,
Pasadena, TX) and pulse-centrifuged for 10 sec, 1000 rpm (250 g)
(Marathon 3000R, Fisher Scientific) to remove bubbles. Using a
multimode plate reader (SpectraMax M5, Molecular Devices), the
absorbance was recorded at 425 nm and 390 nm in two-
wavelength mode, or at between 350 nm to 500 nm in 10 nm
increments (16 measurements total/compound) in spectral mode,
with 6 reads per well.
Analysis of plate readings
Data were manipulated and analyzed using Microsoft Office
Excel 2007. Values from each pair of test and reference plates
were read and exported to the pre-programmed Excel template
and processed using the algorithm shown in Table S1. First,
each plate was processed separately to account for the effects of
DMSO and protein background. In this step absorbance values
for each individual wavelength were averaged across all 32 wells
in columns 1 and 2. The resulting value was subtracted from the
absorbance measured at the same wavelengths for each
individual compound (columns 3 through 22) or reference
(columns 23–24). Next, the corrected absorbance values in the
reference plate (Table S1B) were subtracted from those of
corresponding wells in the test plate (Table S1A), yielding the
absorbance contributions at each wavelength solely due to
protein-compound interactions. In two-wavelength mode,
DA=A4252A390 was calculated for each compound and plotted
against the corresponding well (Figure 1). Due to the Soret band
shifting red, DA is a positive value for type II hits. In spectral
mode, corrected absorbance values were directly plotted against
wavelength. The resulting difference binding spectra were
overlaid and inspected visually to eliminate false-positive hits
and to rank the remaining compounds in the order of their
affinities to the CYP51 target (Figure 2).
Figure 1. High throughput assay overview. T. cruzi CYP51 target is shown clipped by plane through the substrate binding tunnel (top, center).
Type II difference spectrum is recorded for 1 mM CYP51 at saturated concentration of reference compound (top, right). Screen plates were prepared in
duplicate, A and B, with target protein loaded only in A set (left). HTS scatter plot shows absorbance differences of test compounds (DA=A4252A390)
measured using the two-wavelength detection mode; each point represents a single test compound (bottom, center). Overlapped spectra are shown
for a sub-micromolar hit re-evaluated in spectral mode at four serial dilutions (bottom, right).
doi:10.1371/journal.pntd.0001736.g001
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Ranking positive hits in spectral mode
For ranking purposes, compounds were scored according to the
appearance of their spectra. A score of 0 was assigned to false-
positive compound hits that failed to demonstrate characteristic
type II spectra (Figure 2A). The hits that showed concentration
dependence with no overlapped spectra received a score of 1,
while hits with any 2 or 3 overlapped spectra received scores of 2
and 3, respectively (Figure 2B–D). Compounds whose three
highest concentration spectra overlapped received a score of 4
(Figure 2E). Finally, hits having all four spectra overlapped,
including spectra for the highest and lowest concentrations,
received a score of 5 in this system (Figure 2F).
Low throughput UV-vis binding assay
Hit validation in the low throughput UV-vis binding assay was
performed according to a previously published but somewhat
modified protocol [14]. UV-vis absorption spectra were recorded
on a Cary scanning spectrophotometer (Varian) in the 1-cm path
length quartz cuvette at 23uC in 100 mM potassium phosphate
buffer, pH 7.5, containing 10% glycerol, with CYP51 concentra-
tion of 0.5 mM. Compound solutions used for titration were
prepared in DMSO at 100 mM and added in 2-ml aliquots to each
3 ml sample using a P2 pipetman (Gilson). Binding affinity of hits
was estimated using the quadratic tight-binding equation [27]:
Aobs~ Amax=2Etð Þ SzEtzKDð Þ{ SzEtzKDð Þ2{4SEt
h i0:5 
ð1Þ
where Aobs is the absorption shift determined at any ligand
concentration; Amax is the maximal absorption shift obtained at
saturation; KD is dissociation constant for the inhibitor-enzyme
complex; S is the ligand concentration; Et is the total enzyme
concentration.
Mammalian cell culture and T. cruzi maintenance
Bovine embryo skeletal muscle cells [28] or mouse C2C12
myoblasts (ATCC#CRL-1772) used in the cross-validation assay,
were cultivated respectively in RPMI 1640 medium supplemented
with 5% horse serum and Dulbecco’s Modified Eagle’s Medium
H-21 containing 4.5 g/l glucose (DMEM H-21) (Cell Culture
Facility, UCSF), supplemented with 5% fetal bovine serum (FBS)
(Sigma Chemical Co., St. Louis, MO, USA), 25 mM HEPES,
2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomy-
cin. T. cruzi CAI-72 trypomastigotes [28] were obtained from
supernatant of infected cultures 4 to 7 days post-infection. Cultures
were maintained at 37uC in an atmosphere of 5% CO2. To
harvest parasites, the supernatant of infected cultures containing
released trypomastigotes was collected and centrifuged at 600 rpm
for 5 min to remove cell debris; the pellet was then discarded and
the trypomastigotes remaining in the media were concentrated by
spinning the culture tubes at 3300 rpm for 15 minutes. The
parasite pellet was re-suspended in 2–5 ml of fresh media.
Trypomastigote concentration was determined using a Neubauer
hemocytometer.
Hit cross-validation in T. cruzi-infected mammalian cells
Compound cross-validation in T. cruzi infected skeletal myo-
blasts (bovine embryo skeletal muscle or C2C12 lineage) was
performed according to the protocol adapted from Engel and co-
authors [29]. Compounds stored as 10 mM stocks in DMSO were
freshly diluted immediately prior to use. Final concentrations of
DMSO never exceeded 0.4%, which has been shown to be non-
toxic both for parasites and mammalian cells. To prepare plates
Figure 2. Scoring positive hits in spectral mode. Absorbance was monitored at four serial dilutions for each tested compound. (A) Lack of
characteristic spectra-score 0; (B) concentration dependence with no spectra overlap – score 1; (C) any two spectra overlap-score 2; (D) any three
spectra overlap-score 3; (E) three highest concentrations overlap-score 4; (F) all four spectra overlap-score 5.
doi:10.1371/journal.pntd.0001736.g002
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for the assay, skeletal myoblasts cultured in 75–150 cm3 flasks
were washed once with phosphate buffered saline (PBS) and then
incubated with 0.25% trypsin in PBS for 1–3 minutes for
detachment. The trypsin solution was removed and myoblasts
were released from the flask bottom. Fresh medium was added and
cell concentration was determined using a Neubauer hemocytom-
eter. Myoblasts in 50 ml of culture medium were transferred to the
clear-bottom wells of black 96-well plates (Greiner Bio-One,
#655090) at a density of 1500 cells/well and infected with 50 ml
trypomastigote culture at 7500 parasites/well (1:5 ratio). The cells
were allowed to adhere and spread for 24 h in the incubator
before the media was removed and 100 ml of fresh medium
containing 0, 0.04, 0.12, 0.37, 1.10, 3.30 or 10 mM of test
compound was added to each well, followed by 72 h incubation at
37uC in an atmosphere of 5% CO2. Posaconazole was used as a
positive control at the same concentrations as the test compounds.
The cells were then fixed by adding 100 ml/well of 8%
formaldehyde in PBS, resulting in a 4% working concentration
of formaldehyde. To stain the nucleus of the host cell and the
nucleus and kinetoplast of parasites, cell membranes were first
permeabilized by washing once with 100 ml of 0.1% Triton X-100
in PBS, then treated for 1 h with 0.2 mg/ml of the fluorescent
DNA dye, 4,6-diamidino-2-phenylindole (DAPI), followed by one
wash with PBS. The fixed plates were kept at 4uC and protected
from light until images were acquired.
Image acquisition and data analysis
Plates were allowed to equilibrate to room temperature and
images were acquired by the IN Cell Analyzer 2000 (GE
Healthcare) with a 206 objective, 5 fields per well, with 350/
50 nm and 460/40 nm fluorescent excitation and emission filters.
In the absence of drug cytotoxicity, at least 800 cells were imaged
and counted per well. The images were processed and analyzed by
IN Cell Analyzer Developer 1.6 software. The size parameters
used to segment host and parasite organelles were 125 mm2 for
host nucleus, and 1–2 mm2 for parasite nucleus/kinetoplast. Since
DAPI also strongly stains host heterochromatin regions that
display as shapes resembling parasites (Figure 3), particles co-
localized to host nuclei were excluded from quantification, while
parasite aggregates near the host nucleus were counted as infected
cells. Numbers of host cells and intracellular amastigotes were
determined based on host cell and parasite nucleus and parasite
kinetoplast quantification, providing a measure of growth inhibi-
tion during the first 72 h of post-infection treatment compared to
untreated controls.
Trypanocidal assay
Compounds cross-validated with low EC50 against T. cruzi
infected cells were further evaluated to determine the ‘‘cidal’’
concentration at which host cells are effectively cured, using the
protocol adapted from Engel et al 1998 [30]. To allow long term
treatment and avoid culture overgrowth, C2C12 myoblasts were
seeded at low density in 96 well plates (103 cells/well) and cultured
with DMEM H-21 medium supplemented with low FBS
concentration (1%), 25 mM HEPES, 2 mM L-glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin. The cells were
infected with T. cruzi trypomastigote strain CAI/72 (5 parasites/
cell) for 24 h and treated with 0, 0.04, 0.12, 0.37, 1.10, 3.30 or
10 mM test compounds in 100 ml of medium for 14 days. During
the course of treatment, medium supplemented with test
compounds was replaced every 72 h. After 14 days, drug pressure
was withdrawn and incubation continued in the compound-free
medium for another week, during which cultures were monitored
for reappearance of T. cruzi trypomastigotes in the supernatant.
Lipid analysis of T. cruzi amastigotes
To grow intracellular amastigotes for lipid analysis, C2C12
mouse skeletal myoblasts (46106 cells) cultured in 150 cm2 flasks
as described above were infected with 806106 trypomastigotes for
24 h. The cultures were treated with test compounds 72 h post-
infection at concentrations 56 below cidal to avoid completely
killing the parasites. Posaconazole at 100 nM was used as a
positive control. The cysteine protease cruzain inhibitor K777 [31]
at 1.6 mM was used as a negative control to ensure that T. cruzi
inhibition via other pathways did not affect composition of the
membrane sterols. Cells were harvested 96 h post-infection and
after 24 h of drug treatment. Cell detachment was initiated by
brief treatment with 10 ml of 0.25% trypsin in PBS, followed
promptly by replacement with 10 ml of fresh media containing
FBS. Harvested cells were washed 36 with 25 ml of PBS to
remove FBS and released trypomastigotes. The suspension of
infected cells was then transferred to a glass tube and centrifuged
at 2000 rpm for 5 min. After washing with PBS, 2 ml of
chloroform-methanol solution (2:1 ratio) was added to re-suspend
the cell pellet. Organic solvents were then evaporated under N2
flow, allowing the pellet to dry.
For total lipid extraction, the dry cell pellet was treated with
2 ml chloroform for 24 h. Polar molecules were removed by
washing the organic phase 36with 3 ml water. The organic phase
containing the sterols was subsequently dried on an evaporator
under N2 flow. The lipids were re-suspended in 2 ml of
chloroform-methanol (9:1 ratio), washed again 36 with 3 ml
water, dried under N2 flow and re-suspended in acetonitrile. After
an additional wash 36with 3 ml water, the acetonitrile was dried
under an N2 stream. Extracted dry sterols were re-dissolved in
hexane and derivatized with N,N-bis(trimethylsilyl)-2,2,2-trifluor-
oacetamide (BSTFA) (Pierce) by incubating at 37uC for at least
2 hours. Sterols as their trimethylsilyl (TMS) derivatives were
analyzed by gas chromatography and mass spectrometry (GC-
MS). GC-MS analysis and lipid identification were performed as
described previously [14].
Results
Primary screening in two-wavelength mode
Given the large size of the library, we reasoned that use of the
two-wavelength detection mode would increase the throughput
potential of the assay above that of the multi-wavelength (spectral)
mode previously described [21,22]. Thus, in the primary screen,
detection was carried out at 425 nm and 390 nm, corresponding
to the maxima and minima of type II difference binding spectra,
the difference in absorbance DA=A4252A390 being the discrim-
inative criterion (Figure 1). The DA of the DMSO control
averaged 0.00060.003 (mean 6 standard deviation), while DA of
the reference was 0.04360.004, resulting in the assay Z9-factor
value of 0.5860.04. Standard deviation was calculated for 528
measurements. The amplitude of the absorbance difference is
directly proportional to the fraction of CYP51 target bound to the
compound, with the maximal value of ,0.04 corresponding to full
displacement of the iron axial water ligand as a result of saturation
of the active sites. 374 compounds (0.35% of the whole library)
were outliers with DA.0.04. We speculate that these compounds
fell into the outlier category because of spectral or solubility
characteristics. Twenty of these outliers were selected for re-
Target-Based Small-Molecule Screen against CYP51
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evaluation in spectral mode and were confirmed to lack
characteristic absorbance features.
Re-evaluation of two-wavelength hits in spectral
screening mode
We identified false-positive hits in the two-wavelength pool by
re-evaluating select compounds in spectral mode. 2,718 com-
pounds with 0.016,DA,0.04 were first analyzed using Accelrys
software (Accelrys, Inc., San Diego, California) for structural
differences and similarities. Briefly, the fingerprint of each
compound was determined using a proprietary extended-connec-
tivity algorithm, EFCP_6, and folded to 256 bits for efficiency of
comparison [32,33]. A maximal dissimilarity [34] partitioning
algorithm [35] employed the Tanimoto distance between these
fingerprints to cluster the compounds into 30 groups. Similarly,
374 outliers with DA.0.04 were divided in 10 groups. Two
representatives (one with maximum DA and another with median
DA) were selected from each group, resulting in 80 compounds
subjected to evaluation in full spectral mode. Evaluation was
performed for four serial dilutions from 2 mM to 12 mM, followed
by ranking of hits using the 0–5 scoring system (Figure 2). All 20
compounds selected from the outlier pool fell into the false-positive
category (score 0). Among the remaining 60 compounds, 22 (36%)
were validated as positive hits, including 7 compounds scored 4 or
5, with only one having all four spectra overlapped (score 5)
(Table S2).
Selection and re-evaluation of the 475 additional two-
wavelength hits in spectral mode
A visual inspection of the first 22 hits shown to be positive in
both two-wavelength and spectral modes confirmed that 17
possessed nitrogen-containing aromatic heterocycles capable of
coordinating to the heme iron in the active site of CYP51 (Table
S2). The remaining five contained aliphatic amine groups.
Informatics analysis of the entire 104,000 compound library
identified 6,643 compounds having heterocycle pharmacophores
with an accessible nitrogen atom in their structures; 1,274 of these
were identified in the two-wavelength primary screen as demon-
strating absorbance differences in the range of positive hits. Strict
enforcement of the Lipinski ‘‘rule of five’’ [36] narrowed the pool
to 1,172 compounds. Hit scaffolds, defined as consisting of .2
rings and .3 members, were clustered by structural similarity and
organized into a hierarchical tree using SARvision Plus 3.1
(Altoris, San Diego) software. Based on these criteria, 188 scaffold
groups plus 155 singletons were identified. 320 compounds were
picked from the scaffold groups and combined with the 155
singletons, yielding 475 compounds to be re-tested in the spectral
mode and ranked using the 0–5 scoring system shown in Figure 2.
Among these, only 21 compounds (4%) failed to demonstrate
characteristic type II spectra, while the remaining 454 compounds
showed the spectral characteristics of positive hits, including 134
hits which received a score of 4, and 44 hits with a score of 5, both
values suggesting low nanomolar binding affinity as approximated
Figure 3. Cross-validation of hit compounds in intracellular T. cruzi amastigotes. Segmented images of DAPI-stained T.cruzi-infected
myoblasts processed with image processing software are shown for cells cultured after 72 h treatment with Compounds 1 (C, E, G) or 13 (D, F, H) at
indicated concentrations. Nuclei of host cells are highlighted in blue and nuclei and kinetoplasts of parasites are highlighted in red. The inserts show
original DAPI staining in blue. Note the elimination of intracellular amastigotes at 0.123 mM and 10 mM of Compound 1 (E, G) and 10 mM of
Compound 13 (H). In the negative control, DMSO-treated myoblasts show abundant parasitemia (A). Posaconazole was used as a positive control
(B). Bars = 20 mM.
doi:10.1371/journal.pntd.0001736.g003
Figure 4. Nitrogen-containing aromatic heterocyclic pharmacophores. Distribution of nitrogen-containing aromatic heterocyclic
pharmacophores among 185 positive hits with binding score 4 or 5 (A) echoes their frequency in the library (B). R represents diverse chemical
structures as shown in Table S3.
doi:10.1371/journal.pntd.0001736.g004
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by equation (1). Combined with 7 previously identified hits, they
constituted the 185 high affinity hits listed in the Table S3. The
high target concentration dictated by the assay’s sensitivity did not
allow further discrimination of positive hits by their affinities in
HTS format.
Based on the structure of the putative heme Fe-coordinating
modules, 185 hits can be divided in six unevenly populated
categories (Figure 4A). The number of compounds populating
each category varied from 1 to 92. This distribution reflects the
frequency of each category in the library (Figure 4B), suggesting a
lack of preference for the Fe-coordinating heterocycle as scored by
this assay. Each of the 6 categories was further subdivided into
clusters sharing more extensive structural similarities among the
members (Figure S1). Some clusters had a higher number of T.
cruzi-active hits (highlighted green in Figure S1) than others.
Cross-validation of hits in T. cruzi-infected mammalian
cells
The set of 475 compounds plus the 80 hits previously validated
in spectral mode were cross-validated in T. cruzi-infected myoblast
cells using an image-based medium throughput assay [29]
(Figure 3). Posaconazole was used as a positive control with an
EC50 of 1 nM. EC50 was determined as a concentration of
compound corresponding to 50% inhibition of parasite endocy-
tosis and intracellular growth, the calculation being based on the
sigmoidal dose-response curve of compound-induced inhibition of
the T. cruzi infection index (i.e., the percentage of T. cruzi-infected
cells in culture multiplied by the mean number of parasites per
infected cell).
Of the 497 cross-validated compounds, 57 exhibited anti-T.
cruzi activity with EC50 below 10 mM; this group was notably
enriched with CYP51 binding hit scores of 4 and 5 (36 of 57 total
hits) (Table 1). The remaining hits (21 of 57 total hits, including
the highest rated hit) had binding scores ranging from 1 to 3. The
complete list of the 57 T. cruzi-active hits is shown in Table S4. A
subset of eleven sub-micromolar hits is shown in Figure 5.
Numbering of compounds in Figure 5 and Table S4 is
according to their descending rank order. Both the 185-compound
spectral pool (http://zinc.docking.org/users/lpodust/carts/
185+CYP51+spectral+HTS+hits) and the 57-compound T. cruzi-
active pool (http://zinc.docking.org/users/lpodust/carts/
57+T+cruzi+active+hits) were uploaded to and made publicly
available through the free online resource ZINC (http://zinc.
docking.org) [37].
Comparative analysis of both spectral and T. cruzi-active pools
by logP and MW distributions showed good correlation between
the two pools (Figure 6). A slight enrichment of hits with logP .3
in the T. cruzi active pool (82.5% in the T. cruzi-active pool vs.
78.9% in the pool of spectral hits) was observed (Figure 6A), with
the molecular weight being rather evenly distributed across the
range of 200–400 g/mol, with only a few hits crossing the 400 g/
mol barrier (Figure 6B). Compound 5 with MW of 225 and
calculated logP of 2.6 was the smallest molecule ranked among the
top five T. cruzi-active hits.
Compound 1, [6-(2-bromophenoxy)hexyl]imidazole, (MW of
323, logP of 4.2) was ranked first with an EC50 of 70 nM and HTS
binding score of 2. Upon more rigorous validation in low
throughput assays, Compound 1 was shown to have at least low
nanomolar binding affinity to the target (Figure 7) and an EC50
of 17612 nM averaged from the two independent assays against
T. cruzi amastigotes cultured in mouse myoblasts (Figure 3).
Trypanocidal concentration of Compound 1 was 40 nM in three
independent experiments, which compares favorably to posaco-
nazole (EC50 of 1 nM, trypanocidal at 0.6 nM).
Re-mining data for sub-micromolar T. cruzi hits
Re-mining spectral screening data using the highly rated hits as
molecular scaffolds, emulated a mini-SAR series providing insight
to structure-activity relationships of the hits. For instance,
Compound 1 was structurally distinct compared to azole
antifungal drugs and the majority of positive hits identified in
these studies. Two other highly ranked compounds, 4 and 11,
resembled Compound 1 (Figure 5). Altogether, seven structurally
related hits were characterized by binding scores of 4 or 5, and two
hits, including Compound 1, by scores of 2 (Figure 8). In
addition, two commercial analogs which were not part of the
screened library, Compounds 1a and 1b, were tested. Compound
1a differs by the position of the bromine atom in the
bromophenoxy ring, whereas 1b by the length of the alkyl linker
between imidazole and bromophenoxy rings, both parameters
seem essential for anti-T. cruzi activity (Figure 8). All variations
presented in Figure 8 are associated with reduced EC50, either
due to drop in binding affinity to the target (e.g., Compound 1b or
Compound 11), or possibly to other factors. Thus, relocation of
the bromine atom from the meta- to the para-position of the
bromophenoxy ring (Compound 1a) results in an order of
magnitude drop of anti-T. cruzi activity without detectable change
in KD. However, an enzyme concentration of 0.5 mM defines the
lower limit of the method’s sensitivity at a KD of ,5 nM, a
hundredth of the target concentration, if a plateau in the titration
curve is reached at the stoichiometric enzyme-ligand ratio
(Figure 7 B, C). As differences in affinity between very tight-
binding ligands are reflected in the sharpness of the titration curve,
KD values recovered from fits to experimental data approximated
by equation (1) are disproportionately sensitive to error in data
points near the inflection point. Therefore, caution should be
exercised when comparing the tight binding constants.
Compounds 2, 6 and 7, highly rated in cross-validation, belong
to their own molecular scaffold cluster, which includes 21 hits
(Table S5). Hits rated highest in spectral mode (score 4 or 5) or in
T. cruzi assay are summarized in (Figure 9). Compound 6, methyl
2-amino-6-[2-(3,4-dimethoxyphenyl)ethyl]-7-methyl-5-oxo-4-pyri-
din-3-yl-5,6-dihydro-4H-pyrano[3,2-c]pyridine-3-carboxylate, was
the only one from this cluster validated in low throughput format,
including GC-MS analysis of sterol composition in treated
amastigotes (not shown). Based on this validation, Compound 6
is the runner-up in the series of individually tested compounds,
with estimated KD of 76 nM and EC50 of 80 nM. Further
validation of Compound 2 and other representatives of this cluster
are pending commercial availability of the compounds.
Hit selection for manual validation
Two criteria – anti-T. cruzi activity and/or high screening score
– were used to select commercially available compounds for more
Table 1. Distribution of the 57 hits with EC50 #10 mM by
binding scores.
Find: Symbols Number of hits with EC50 #10 mM (57 total)
1 4
2 9
3 8
4 21
5 15
doi:10.1371/journal.pntd.0001736.t001
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Figure 5. Sub-micromolar T. cruzi inhibitors. aEC50 values obtained against T. cruzi parasites in HTS assay used to rank order the hits.
bIn
parenthesis are EC50 averaged from two independent cross-validation assays for individually repurchased hits.
doi:10.1371/journal.pntd.0001736.g005
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rigorous validation, including impact on the sterol biosynthesis in
T. cruzi amastigotes cultured in mouse myoblasts. A search for
compound vendors was conducted using the online resource
ZINC [37]. Altogether, 32 hit compounds were acquired for
validation in manual low-throughput assays, including eight T.
cruzi-active hits: Compounds 1, 3, 5, 6, 9, 11, 13 and 15 (Table
S6). Binding could not be confirmed for two of the acquired
compounds due to compound precipitation under assay condi-
tions. The other repurchased compounds bound CYP51 with one-
to-one stoichiometry at 0.5 mM protein concentration (Figure 7),
suggesting at least low nanomolar binding affinity as extrapolated
from equation (1). Low EC50 values were confirmed for all tested
T. cruzi–active hits (Figure 5).
GC-MS analysis of membrane sterols
Inhibition of sterol biosynthesis by GC-MS analysis was
confirmed for all individually acquired hits. The major sterol
observed in untreated amastigotes was episterol (peak d in
Figure 10), followed by approximately equal amounts of
fecosterol (e) and cholesta-7,24-dien-3b-ol (peak a). This sterol
composition is consistent with our previously published work [14]
but differs from Liendo and co-authors [5], where 24-methyl-7-en-
cholesta-en-3b-ol (peak c in Figure 10) was identified as a main
sterol of intracellular amastigotes. The most straightforward
explanation for these differences would be the differences in the
lipid extraction protocols used in this work or published elsewhere
[38]. As a result of CYP51 inhibition, two 14-methylated
precursors, lanosterol (f) and eburicol (h) dominated the GC-MS
traces of the strongest CYP51 inhibitors posaconazole and
Compound 1, and were present in amounts comparable to those
of 14-demethylated products for the less potent Compound 13
(Figure 10). Interestingly, fecosterol (e) was completely inhibited
by low concentrations of posaconazole and Compound 1, whereas
episterol (d) persisted. This observation seems difficult to explain in
light of the T. cruzi sterol pathway reported elsewhere [5], in which
fecosterol precedes episterol in the reaction chain.
Cheminformatic analysis of hits
Given an unexpectedly large number of structurally diverse hits,
we used an algorithm implemented in the online cheminformatic
research tool SEA (Similarity Ensemble Approach) (http://sea.
bkslab.org/) [39] to relate CYP51 to other pharmacologic targets by
ligand topology. In SEA, the similarity of protein targets is
established and scored based on the similarity of their ligands using
the probability of a random match, or expectation E-value, as a
scoring function that relates lower E-values to more statistically
significant ligand similarities. Results from probing the molecule
databases implemented in SEA [39] with the 57 T. cruzi-active hits,
either individually or as a pool, indicated CYP51’s similarity to
other P450 drug targets, including thromboxane synthase (CYP5),
fatty acid v-hydroxylases (CYP4), 17a-hydroxylase/17,20-lyase
(CYP17), and aromatase (CYP19). These enzymes have been
targeted by the pharmaceutical industry for cardiovascular disease
[40], metabolic disorders of lipid metabolism and inflammation
Figure 7. Hit validation in binding assay. (A) Hit compound
structures. Compound 13 shows structural similarity to miconazole.
Stoichiometric binding of 1 (B) and 13 (C) to CYP51 at 0.5 mM by UV-vis
titration suggests low nanomolar binding affinity as approximated by
quadratic tight-binding equation (1).
doi:10.1371/journal.pntd.0001736.g007
Figure 6. Comparative analysis of spectral (blue) vs. T. cruzi-active (red) hits. Distribution of the (A) logP and (B) molecular weight (MW)
values.
doi:10.1371/journal.pntd.0001736.g006
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[41], prostate cancer [42], and estrogen receptor-positive breast
cancer [43], respectively. Unexpectedly, these pharmacologic
targets scored substantially higher than sterol 14a-demethylase
(CYP51) itself, giving credence to the idea that molecules directed
against these targets, including drugs that have entered the clinic,
could be examined for potency against T. cruzi CYP51.
Figure 8. Highest rated hit compound cluster. aEC50 values obtained against T. cruzi parasites in HTS assay used to rank order the hits.
bIn
parenthesis are EC50 averaged from two independent cross-validation assays for individually repurchased hits. N/A – not applicable; N/D – not
determined.
doi:10.1371/journal.pntd.0001736.g008
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Another surprise revealed by cheminformatic searching in the
SEA databases is the striking resemblance of the highest rated hit
to inhibitors of glutaminyl-peptide cyclotransferase, an enzyme
unrelated to CYP family either by sequence or structure. This
enzyme catalyzes the formation of N-terminal pyroglutamic acid
whose biological function is either to mediate peptide hormone
interaction with receptors, or to stabilize proteins and peptides
against N-terminal degradation [44]. Human glutaminyl-cyclase
which catalyzes pyroglutamic acid formation at the N-terminus of
amyloid peptides, is potentially involved in the development and
progression of neurodegenerative disorders [44].
Discussion
We designed an HTS assay to identify compounds capable of
coordinating to the heme iron of CYP51. Following target-based
screening and the further validation steps summarized in
Figure 11, we identified 185 high affinity hits and 57 partially
overlapping hits with anti-T. cruzi activity, including a dozen sub-
micromolar inhibitors of T. cruzi infection in mammalian cells.
Hits identified in the primary two-wavelength screen were
evaluated by cheminformatic analysis, spectral screening and
cross-validation against T. cruzi amastigotes. Informatics feedback
Figure 9. Second highest rated hit compound cluster. aEC50 values obtained against T.cruzi parasites in HTS assay used to rank order the hits.
bIn parenthesis is the EC50 obtained in validation assays for individually repurchased hits. N/A - not applicable; N/D - not determined.
doi:10.1371/journal.pntd.0001736.g009
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served to maximize scaffold diversity and reduce the number of
compounds subject to re-evaluation in the more laborious spectral
mode. As a result, the two pools, of 185 and 57 hits, were
structurally diverse with respect to the number, size and
arrangement of rings, as well as the nature of the linkers and
substituting groups constituting the compound frameworks (Ta-
bles S3 and S4). In summary, although two-wavelength mode is
more efficient in terms of throughput, it generated .60% false-
positive hits. Although more time-consuming to read, analyze and
tabulate, the spectral mode is a more comprehensive methodology
than the two-wavelength mode in terms of efficiently filtering and
ranking true positive hits. Overall, based on validation tests for
representative compounds, we expect the set of hits identified in
this work to contain a high percentage of true positive hits and to
be a valuable resource for further development of Chagas Disease
applications.
At the high hit rate we observed, we were unlikely to miss
important chemotypes by excluding 102 compounds violating
Lipinski rule of five from validation in the full spectral mode and
cross-validation in the T. cruzi assay. The process of optimization
generally yields larger and more hydrophobic compounds, and
thus it is industry practice to focus on smaller ‘‘lead-like’’
compounds to allow MW and logP to increase during lead
development [45]. On the other hand, a rationale for looking at
hydrophobic hits in more detail is justified by the fact that the
CYP51 inhibitors itraconazole and posaconazole do not comply
with this rule. The potency of posaconazole in the treatment of
invasive fungal infections is attributed to accumulation of drugs in
the tissues of internal solid organs rather than to free levels of drug
in plasma [46,47]. In isolated cells and solid tissues, both
posaconazole and itraconazole are mostly concentrated in cellular
membranes, which are also the site of their molecular target,
CYP51 [48]. Given that the potent in vivo activity of posaconazole
and other novel CYP51 inhibitors is attributed to their special
pharmacokinetic properties, such as large volumes of distribution
and long terminal half-life [49,50], it may be worth revisiting the
102 hits initially excluded by the Lipinski criteria.
The T. cruzi–active pool contained both high affinity hits (score
4 or 5) and those with lower binding scores (Table 1), suggesting
that low score compounds might have been acting via alternative
mechanisms. To test this possibility, the binding and activity of the
highest rated hit, Compound 1, was confirmed in manual assays.
Compound 1, had activity an order of magnitude higher than any
other hit identified in these studies (Figure 5). At 100 nM
concentration, Compound 1 suppressed sterol biosynthesis in T.
cruzi amastigotes more efficiently than posaconazole (Figure 10),
thus becoming a candidate for further evaluation in an animal
model of infection. Cheminformatic searching in the SEA
Figure 10. GC-MS analysis of the T. cruzi lipid extracts treated
with the CYP51 inhibitors. DMSO and K777 were used as negative
controls; posaconazole served as a positive control. Uninfected host cell
panel (top) demonstrates that chromatographic peaks labeled with
small-case letters from a to i are of T. cruzi origin, corresponding to a -
cholesta-7,24-dien-3b-ol, [M]N+=m/z 454; b - cholesta-8,24-dien-3b-ol
(zymosterol), [M]N+=m/z 470; c - 24-methyl-7-en-cholesta-en-3b-ol,
[M]N+=m/z 472; d - ergosta-7,24-diene-3b-ol (episterol), [M]N+=m/z
470; e - ergosta-8,24-diene-3b-ol (fecosterol), [M]N+=m/z 470; f -
lanosterol, [M]N+=m/z 498; g - 4-methylepisterol, [M]N+=m/z 484; h -
eburicol, [M]N+=m/z 512; i - 24-ethyl-7,24(249)-en-cholesta-dien-3b-ol,
[M]N+=m/z 484. Cholesterol is the only peak originating from host cells.
Increase in the CYP51 substrates lanosterol (f) and eburicol (h) is due to
inhibition of T. cruzi CYP51, as is the decline in the downstream major
products episterol (d), fecosterol (e), cholesta-7,24-dien-3b-ol (a) and
the minor products 4-methyl-episterol (g) and 24-ethyl-7,24(249)en-
cholestadien-3b-ol (i).
doi:10.1371/journal.pntd.0001736.g010
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databases [39] revealed a significant resemblance of the top hit to
inhibitors of P450 drug targets involved in eicosanoid synthesis
and fatty acid metabolism. For example, thromboxane-A synthase
was highly ranked with regard to the top hit and the structurally
related sub-micromolar hits 4 and 11, as were the fatty acid v-
hydroxylases of the CYP4 family. Surprisingly, the lowest E-values
were obtained for glutaminyl-peptide cyclotransferase, which is
unrelated to CYP family by sequence or structure. While the
ability of drugs to bind to unintended targets in the human host
can lead to undesirable side effects, the same binding to a target in
a pathogen infecting a human can cure infection. In the context of
a deficit of drugs for neglected diseases, the unexpected
promiscuity of CYP51 encountered in this work could be utilized
in a ‘‘piggy-back’’ strategy [51,52] for identifying a chemical
starting point for anti-parasitic therapy development, while
structure-activity relationships derived from parasite assays could
lead to disease-specific clinical candidates [53–56].
The structural motif present in the cohort of antifungal azole
drugs was apparent in both pools. For instance, hit 1, 2-(4-
chlorophenoxy)-1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)etha-
none (binding score 5) (Compound 13), which ranked thirteenth in
the anti-T. cruzi activity assay, resembled miconazole (Figure 7A),
one of the first broad-spectrum antimycotic agents and the
conazole progenitor of orally active antifungal agents such as
ketoconazole, itraconazole, posaconazole, fluconazole and vorico-
nazole [15]. Manual UV-vis titration confirmed that Compound
13 binds and saturates CYP51 at equimolar 0.5 mM concentra-
tions, suggesting at least low nanomolar binding affinity
(Figure 7C). According to the SciFinder online resource,
compounds with close structural similarities to Compound 13
were patented in the 1970’s as potent fungicides. To confirm a
relationship between this structural motif and biological activity,
we extracted membrane sterols from T. cruzi amastigotes isolated
from infected mouse myoblasts treated with Compound 13.
Consistent with the inhibition of CYP51, GC-MS analysis showed
an increase in lanosterol and eburicol precursors and a concom-
itant decline in episterol, fecosterol and other 14-demethylated
intermediates (Figure 10). Compound 13 was effective against T.
cruzi amastigotes with an EC50 of 1.3 mM and was trypanocidal at
2.5 mM.
The shape of the posaconazole molecule defines its binding
mode to CYP51. Its long ‘‘tail’’ group extends into the substrate-
binding tunnel [24,57]. In the mouth of the tunnel, posaconazole
adopts alternative conformations and makes multiple points of
contact with amino acid residues on the protein surface [24].
Extensive interactions of posaconazole with catalytically non-
essential residues in CYP51 are strikingly consistent with the
pattern of drug resistance in fungi. The points of posaconazole
contact are mutation hot spots in azole-resistant isolates of the
pathogenic fungi Aspergillus fumigatus and Candida albicans [24].
Some of these mutations confer cross-resistance to all azole drugs
[58–61]. The spread of drug resistance due to mutation of the
target in response to therapy might be avoided in T. cruzi if the
binding properties of new inhibitors were improved using target
Figure 11. Flowchart diagram of screening and validation steps.
doi:10.1371/journal.pntd.0001736.g011
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structure as a guide. This concept has been successfully used for a
panel of 9 FDA-approved HIV protease inhibitors developed with
extensive use of structure-based drug design [62]. In order to stay
within a substrate envelope and focus hit-to-lead optimization
chemistry on main-chain interactions, we are pursuing co-
crystallization of low molecular weight hits with CYP51 for x-
ray structure analysis. Compared to the larger posaconazole (MW
700 g/mol), the molecular weight of hits active against T. cruzi
ranged from 215 to 480, with the majority (39 of 57) below 360;
Compounds 1 and 13 are 323 and 348 g/mol, respectively.
Furthermore, with its ‘‘fragment-like’’ characteristics [63] of the
lowest molecular weight and logP among the sub-micromolar T.
cruzi hits, Compound 5 has good prospects in hit-to-lead
optimization, as does one of the smallest high affinity spectral
hits, 5,8-dibromoisoquinoline (Compound 45 in Table S3; MW
287 g/mol), consisting only of an iron-coordinating heterocyclic
module.
In conclusion, diversification of leads for CYP51 inhibitors
should offer the medicinal chemist new choices in terms of
chemical accessibility and prospects for lead optimization.
Multiple leads lower the risk of drug attrition in the case of
undesirable ADMET properties and also cover a patent-free
space, one of the keys to the successful anti-Chagasic therapy of
the future. In the course of this work we have (i) further
developed a UV-based high throughput screening methodology
for P450 enzymes; (ii) diversified the chemical scaffold space for
CYP51 inhibitors; (iii) identified a potent T. cruzi inhibitor and a
diverse array of low molecular weight hits with high affinity to
CYP51 for hit-to-lead optimization; (iv) related CYP51 to other
pharmacologic targets by computational ligand chemistry. This
effort has allowed us to identify molecules already produced by
pharmaceutical companies for future experimental testing against
T. cruzi.
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